Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of two substances, cocaine and N-acetylcysteine. Cocaine is a central nervous system stimulant and local anesthetic with high abuse potential, acting primarily by blocking the reuptake of dopamine, norepinephrine, and serotonin in the brain. N-acetylcysteine (NAC) is an antioxidant and cysteine prodrug that restores glutamate homeostasis in the brain by modulating the cystine-glutamate exchanger (system xc−). While there are no approved pharmaceutical products combining these agents for clinical use, research has investigated NAC as a pharmacological intervention to mitigate cocaine-induced neurotoxicity or reduce relapse risk in individuals with cocaine dependence. Preclinical studies show that NAC can prevent or reverse some of the neurochemical changes induced by repeated cocaine exposure—such as disruption of glutamate signaling—and may reduce drug-seeking behavior[2][3][4][5]. In vitro studies also suggest NAC can protect astrocytes from acute cocaine toxicity via its antioxidant properties[5]. Clinical trials indicate that NAC may decrease cue-induced craving or desire for cocaine among abstinent users but does not directly antagonize acute effects of administered cocaine[2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cocaine + N-acetylcysteine.